Toss MS, et al. - Authors characterized the legumain protein expression in ductal carcinoma in situ (DCIS) and evaluated its prognostic significance. They immunohistochemically assessed legumain in a tissue microarray of a well-characterized cohort of DCIS. Better patient risk stratification was provided by legumain when incorporated with other risk factors. Findings suggested an association of high legumain expression with poor prognosis in DCIS and this could be a potential marker to predict DCIS progression to invasive disease. For all recurrences and for invasive recurrences, legumain was an independent predictor of a shorter local recurrence-free interval.